Ancient Diseases Return as Trump's Policies Unravel 50 Years of Progress

What if 50 years of medical progress could vanish overnight? That's exactly what's happening as the Trump administration's USAID cuts leave 140 million people without access to treatments for diseases that have plagued humanity since ancient times.

The withdrawal isn't just about budget numbers—it's about abandoning a boulder of disease elimination partway up the mountain, as researchers studying these conditions put it. And when that boulder rolls back down, it crushes decades of painstaking work.

The Ancient Enemy That Never Left

River blindness and elephantitis sound like medieval afflictions, but they're very real threats in 2026. These parasitic infections have been documented since 2000 B.C.—Egyptian pharaoh statues show telltale signs of lymphatic filariasis, where limbs swell to grotesque proportions.

Unlike headline-grabbing diseases like COVID or malaria, these "neglected tropical diseases" don't kill quickly. Instead, they condemn victims to lifelong disability and social stigma. River blindness sends microscopic worms migrating through skin into eyes, causing inflammation that leads to permanent blindness. Elephantitis blocks lymphatic vessels, causing legs, arms, or genitals to balloon into elephant-like appendages.

The cruel irony? Both conditions are entirely preventable with medications that cost pennies per dose.

The Sisyphean Struggle

Since 1974, the global health community has waged war against these ancient foes through mass drug administration campaigns. The strategy was elegantly simple: give everyone in affected areas preventive medications, regardless of whether they're infected.

Merck donated ivermectin—a Nobel Prize-winning drug. GlaxoSmithKline and Eisai provided additional antiparasitic medications for free. The World Health Organization coordinated distribution to remote villages across Africa, Asia, and Latin America.

The results were stunning. By 2024, 871 million people no longer needed preventive treatment for lymphatic filariasis. 21 countries eliminated the disease entirely, while 5 countries conquered river blindness.

Then came 2025.

When the Boulder Rolls Back

The Trump administration's sudden USAID defunding didn't just cut a budget line—it severed the logistical backbone of disease elimination programs. Over 40 drug distribution campaigns ground to a halt. The ripple effects accelerated when the U.S. withdrew from WHO membership in January 2026, removing the largest financial contributor to global health coordination.

For parasitic diseases, there's no such thing as "pause." Stop treatment, and the worms multiply. Infection rates rebound. The carefully constructed firewall against transmission crumbles.

Researchers compare it to King Sisyphus's eternal punishment—rolling a boulder uphill only to watch it crash back down. Except this isn't mythology. Real people will go blind. Real children will develop disabilities that could have been prevented.

The Domino Effect Nobody Talks About

The immediate crisis extends far beyond the 140 million people who missed treatments in 2025. These diseases create poverty traps—infected individuals can't work, families spiral into debt paying for care, and entire communities become economically devastated.

When disease elimination programs collapse, pharmaceutical companies face a dilemma. They've donated billions of dollars worth of medications, but without distribution networks, those drugs sit unused in warehouses. The entire model of public-private partnership for global health hangs in the balance.

Meanwhile, countries that successfully eliminated these diseases now worry about reintroduction. Parasites don't respect borders. A resurgence in neighboring regions could undo their hard-won victories.

Sarah Greene has received funding from the NIH. Philip Budge has received funding from the Gates Foundation and the NIH, and is a member of the Infectious Diseases Society of America.